GENOMIC RESOURCES FOR THE ZEBRAFISH NIH GUIDE, Volume 26, Number 39, December 5, 1997 RFA: DK-98-006 P.T. National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Child Health and Human Development National Cancer Institute National Eye Institute National Heart, Lung, and Blood Institute National Human Genome Research Institute National Institute of Alcohol Abuse and Alcoholism National Institute on Deafness and Other Communication Disorders National Institute on Drug Abuse National Institute of General Medical Sciences National Institute of Mental Health National Institute of Neurological Disorders and Stroke National Center for Research Resources Letter of Intent Receipt Date: March 6, 1998 Application Receipt Date: April 10, 1998 PURPOSE The purpose of this Request for Applications (RFA) is to solicit applications as part of an effort to create resources that will facilitate the mapping and positional cloning of genes in the zebrafish. The specific objectives to be accomplished are: (1) the generation of a genetic map with a resolution of 0.3 cM or better; (2) the development of Expressed Sequence Tags (ESTs) both from existing libraries and also from new cDNA libraries from specific developmental time points and tissues generated under this RFA; and (3) creation of a physical (radiation hybrid) map of the zebrafish genome. This RFA is intended to stimulate development of a critical tool for research on zebrafish. Additional future initiatives are anticipated as part of the trans-NIH effort to encourage work using this model system, and will build on the present RFA. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for getting priority areas. This RFA, Generation of Genomic Resources for the Zebrafish, is related to many priority areas. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone: 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) individual project grant (R01) mechanism. Applications that address any one or all of the objectives listed above are encouraged. Because the NIH wishes to retain maximum flexibility in organizing the best possible overall program, it is possible that, in the case of an application proposing to address more than one objective, only one component would be funded. Therefore, applicants who propose to address more than one of the objectives should organize the application in individual sections, each describing the approach proposed for a single objective; individual budgets also should be proposed for each objective. A summary budget for the entire application should be included, and the cover page should state the total funds requested (direct and total costs). All investigators funded under this initiative will be expected to work together cooperatively so that the resources developed will be of maximum usefulness to the community. The total project period for applications submitted in response to the present RFA may not exceed three years. The anticipated award date is September 30, 1998. This RFA is the result of a trans-NIH initiative with participation of the Institutes listed above, working though the Cross-NIH Zebrafish Coordinating Committee, under the co-chairmanship of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Child Health and Human Development (NICHD). The principal awards will be made through the NIDDK and will be managed by the NIDDK together with the National Human Genome Research Institute (NHGRI) and the other participating institutes through the Cross-NIH Zebrafish Coordinating Committee. This RFA is a one-time solicitation. Future applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. FUNDS AVAILABLE Approximately $4.0 million (including direct and indirect costs) will be available for this initiative in Fiscal Year 1998 and for each of the two subsequent years. It is anticipated that three to six awards will be made. Proposed funding levels are subject to change due to budgetary, administrative and/or scientific considerations, and are dependent upon the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the participating ICs, the award of grants pursuant to this RFA also is contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background Mutational analysis of development has proven to be a powerful tool to determine the events that result in patterning and morphogenesis of the embryo. As experimentation in Drosophila melanogaster and Caenorhabditis elegans has established, mutational studies combined with genetic combinatorial analyses can identify specific genes that dictate embryonic development and clarify the pathways in which they function. The work in simple invertebrate systems has established that remarkable evolutionary conservation exists of the genetic programs that determine embryo formation, including such early patterning events as formation of the embryonic axes, but also including later events such as development of eye, heart, and other organs. While the invertebrate systems are extremely powerful, many aspects of patterning and morphogenesis of the vertebrate embryo cannot be studied in these systems. The vertebrate embryo has many features not present in other models, including the substantially different organization and greater complexity of the nervous system and the fact that some vertebrate organs have no clear cognates in the simpler invertebrates. Thus, understanding human development will require application of experimental approaches to the formation of the vertebrate embryo. Some assessment of mutations that affect development has been possible in the mouse, but the mouse embryo is inaccessible in utero throughout much of its development. Consequently, mutational studies in this species have been largely limited to defects in post-natal maturation. In addition, the relatively long generation time and substantial costs of maintaining large mouse colonies has limited the applicability of genetic approaches. The zebrafish, Danio rerio, has a number of valuable features as a model organism for study of vertebrate development. The embryos are transparent and accessible throughout development. It is possible to generate haploid progeny, which are viable for up to five days, and also homozygous diploid progeny that carry only maternal (or paternal) genetic information. Many features of zebrafish development have been characterized, including early embryonic patterning, and some aspects of cell fate and lineage determination. Because of their relatively short reproductive cycle, the large number of progeny that can be produced, and the relatively small space needed to maintain large numbers of offspring, the zebrafish is an efficient vertebrate model system for genetic analysis. Two large-scale screens have been performed to date and the transparent embryos screened for defects in overall embryonic pattern, morphogenesis or organ formation. As reported in the December 1996 issue of Development, these screens have identified a substantial number of mutations that affect the formation of organ systems, including defects in the nervous system, skeletal muscle, craniofacial development, the kidney and endocrine organs, the cardiovascular and gastrointestinal systems, and the sensory cells of lateral line systems relevant to auditory and vestibular function. For most of these mutations, the gene defect has not yet been identified. It is likely that many of these mutations affect genes relevant to human development and disease processes such as cancer and neurodegenerative diseases. Some genomic resources already exist to facilitate identification of the molecular defects that underlie these mutations. The zebrafish genome is estimated to consist of approximately 1.7 X 103 Mb or about 2,500 cM. Preliminary analysis suggests large blocks of synteny between the zebrafish and human genomes. Currently, three genetic maps exist, consisting of approximately 500 microsatellite markers, 600 Random Amplified Polymorphic DNA markers (RAPDs), and more than 125 mapped genes. Several radiation hybrid (RH) panels have been constructed, and their utility for large-scale physical mapping is currently being evaluated. It is anticipated that an RH panel of reasonable quality will be available to the research community. Large insert (BAC, PAC and YAC) genomic libraries also exist and are publicly available. The utility of these resources is limited, however, and the mapping infrastructure is insufficiently developed to fully exploit the power of the genetics of this organism. Objectives and Scope The principle objective of this RFA is to solicit applications for research projects that will use state-of-the-art methods, and that will develop any necessary new technologies, to generate genetic and physical maps of the zebrafish genome and to do so rapidly, efficiently, and at low cost. These objectives are set with a view towards providing genomic tools that will be used by the community for the molecular identification of the genes responsible for the existing mutant phenotypes. Beyond this immediate utility, these resources and tools ultimately can be applied to the comprehensive analysis of the complete zebrafish genome. Emphasis will be placed on the implementation of mechanisms to ensure accessibility and ease of use of zebrafish genomic information. 1) Generation of an Improved Resolution Genetic Map A high-resolution meiotic map would be invaluable for positional cloning of genes revealed to be of interest by mutational screening. This RFA seeks to place up to 10,000 polymorphic markers on the zebrafish map. The long-term objective is to achieve a genetic map with the resolution of 0.1 cM; while the applicant need not propose making a map of this resolution, it should be clear that continued effort could produce such a map. The specific types of markers are not stipulated, but could include RAPD's, CA repeats, single nucleotide polymorphisms or other polymorphic markers. Generation and mapping of polymorphisms associated with cloned genes (including those identified by ESTs generated elsewhere under this RFA) should be included in the proposal, as well as generation and mapping of anonymous markers. The markers should be generated through the best available procedures. Applicants need to address the efficiency, throughput, robustness and cost of the types of marker proposed, in addition to their scientific value. Markers should be placed on meiotic panels derived from the progeny of a cross between two strains. The application may propose to map markers on existing panels, or may propose creating new panels with enhanced polymorphism. Choice of strains should be justified. Attention must be given in the application to the integration of any new map information with existing maps, genetic and physical. Provision must also be made for distribution of mapping reagents to the community, and ensuring prompt availability of map data to the community in coordination with informational mechanisms implemented through this RFA (see Data and Resource Sharing below). 2) Generation of cDNA Resources and EST Sequencing To provide additional markers for mapping, proposals are sought to generate and sequence at least 100,000 Expressed Sequence Tags (ESTs) from multiple libraries. Besides their use in mapping, it is anticipated that these ESTs will provide a generally useful resource for other areas of zebrafish research, including functional analyses, candidate approaches to positional cloning, establishing syntenic relationships between zebrafish and human, etc. Initially this sequencing should utilize currently available libraries, but to the extent that new libraries are needed to optimize yield of new sequences, the production of additional libraries should be undertaken, as described below. Sequences should be generated both from 5' ends of cDNAs, to clarify homologies with known genes, and 3' ends, for the purposes of genetic mapping and SSCP analysis, with the rationale for relative proportions of 5' and 3' sequence explained in the application. Applications should address how the strategy proposed will result in maximizing the number of new gene sequences retrieved from a given library. This RFA also seeks to supplement currently available cDNA libraries by the generation of additional cDNA libraries from zebrafish at different stages of development as well as from different tissues of the zebrafish. These libraries, in addition to their utility for generating ESTs, also will be useful reagents for future functional studies outside the scope of this RFA. Current technology allows the production of representational libraries of partial genes or production of more limited libraries of full-length clones, which are generally enriched for shorter genes. In addition, technology exists to create normalized (reduced redundancy) cDNA libraries; the application should justify the methods proposed. The specific mRNA source and method for cDNA library construction is not stipulated. The applicant should justify the type of libraries to be constructed in terms of cost and general scientific utility. Applicants must also include provision to array and distribute the new cDNA libraries. 3) Generation of a Radiation Hybrid Map of the Zebrafish Genome Applications are solicited for the placement of up to 5,000 markers (sequenced genes, ESTs, etc.) on an available radiation hybrid panel. An RH map provides the advantage that non-polymorphic markers can be readily mapped. Applicants must develop a cost-effective strategy for EST mapping and should justify the overall allocation of resources to this component of the initiative. Applicants must make provision to integrate the RH map with existing genetic map information, to distribute any mapping tools developed under this grant, and to disseminate rapidly all mapping data in coordination with informational mechanisms implemented through this RFA (see Data and Resource Sharing below). A meiotic map of high resolution will be of primary utility in positional cloning in the zebrafish, and it is anticipated that most resources available through this RFA will be allocated to optimizing the genetic map. However, an integrated RH map with a density of 5,000 markers will be a valuable adjunct to facilitate positional candidate approaches to molecular cloning. SPECIAL REQUIREMENTS Data and Resource Sharing The utility of genomic information to the community of investigators interested in the zebrafish is heavily dependent upon the existence of mechanisms that facilitate access to this information. The sharing of materials and data in a timely manner has been an essential element in the rapid progress made in construction and use of the human and mouse genetic maps. Public Health Service policy requires that investigators make the results and accomplishments of funded activities publicly available. The advisors to the NIH and the DOE genome programs have developed a set of "NIH-DOE Guidelines for Access to Mapping and Sequencing Data and Material Resources" that address the special needs of genome research. These guidelines call for material and information from genome research to be made available within six months of the time the data or materials are generated. More rapid sharing is encouraged and has become the norm in the genome community. Applications submitted in response to this RFA should include detailed plans for sharing data and materials generated through the grant. Applicants particularly should propose information-handling mechanisms that facilitate easy access to all known genetic and physical mapping data in an integrated format. Integration with the current bioinformatics zebrafish database at the University of Oregon should be facilitated. Since the ultimate use for these maps is to facilitate positional cloning, provision should be made in the application for mechanisms to facilitate members of the community in mapping genes. This could include provision for distribution of reagents created for meiotic mapping or acting as a service center to those wishing to map genes. Where appropriate, grantees may work with the private sector in making unique resources available to the larger biomedical research community at a reasonable cost. The plans proposed for sharing and data release will be reviewed for adequacy by NIH staff prior to award of the grant and the proposed sharing plan will be made a condition of the award. Investigators may request funds to defray the costs of sharing materials or submitting data in their application. Such requests must be justified adequately. Post-Award Management During the course of the grant period, sequencing, mapping and other genomic technologies will improve, and the rate of progress and focus of work supported by projects may change. It is expected that each Principal Investigator will make any necessary adjustment in scientific direction to accommodate the changing environment. In order to ensure that the projects remain focused on appropriate goals, maintain excellent coordination with the other projects funded under this RFA, incorporate new technological advances and make sufficient progress, scientific and programmatic visits to the grantees may be conducted by NIH staff. In addition, applications should include travel funds for the Principal Investigators and the other key investigators on the grant to meet annually with the Investigators on other projects funded through this RFA and with the Cross-NIH Zebrafish Coordinating Committee in the Washington DC area. LETTER OF INTENT Prospective applicants are asked to submit, by March 6, 1998, a letter of intent that includes a descriptive title of the proposed research; the name, address, and telephone number of the Principal Investigator; the identities of other key personnel and participating institutions; and the number and title of this RFA. Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NIH staff to estimate the potential review workload and avoid conflict of interest in the review. The letter of intent is to be sent to: Chief, Office of Scientific Review National Human Genome Research Institute 38 Library Drive, Room 609, MSC 6050 Bethesda, MD 20892-6050 Telephone: (301) 402-0838 FAX: (301) 408-2770 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 5/95) is to be used in applying for these grants. Applications kits are available at most institutional offices of sponsored research and may be obtained from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/710-0267, email: ASKNIH@od.nih.gov. The RFA label available in the PHS 398 (rev. 5/95) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2 of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, plus three signed photocopies, in one package to: CENTER FOR SCIENTIFIC REVIEW (formerly Division of Research Grants) NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) At time of submission, two additional copies of the application must be sent to: Chief, Office of Scientific Review National Human Genome Research Institute 38 Library Drive, Room 609, MSC 6050 Bethesda, MD 20892-6050 Applications must be received by April 10, 1998. If an application is received after that date, it will be returned to the applicant without review. The Center for Scientific Review (CSR) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The CSR will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications previously reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by CSR, and for responsiveness by the participating ICs. Incomplete applications will be returned to the applicant without further consideration. If staff find that the application is not responsive to the RFA, they will contact the applicant to determine whether to return the application to the applicant or to submit it for review in competition with unsolicited applications at the next review cycle. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by NHGRI. The review will evaluate applications in accordance with the criteria for scientific/technical merit stated below. As part of the initial merit review, all applications will undergo a peer review streamlining process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed and assigned a priority score. Applications will receive a second level review by the National Advisory Councils of the participating (ICs). A written critique will be provided for all applications, including those that are not discussed and not scored. The NIH will withdraw from further competition those applications that were unscored and the applicant Principal Investigator and institutional official will be notified. Staff will review the personnel category for appropriate staffing based on the requested percent effort and any changes requested in future years. The total budget request will be reviewed for consistency with the proposed methods and specific aims. The duration of support will be reviewed to determine if it is appropriate to ensure successful completion of the recommended scope of the project. Review Criteria o Significance: Does this study address the development of important genome resources to the scientific community? If the aims of the application are achieved, how will it improve the physical or genetic map of the zebrafish? What will be the effect of these studies on the zebrafish resources? o Approach: Are the conceptual framework, design, methods, and analyses appropriate and adequate to accomplish the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? Is the scientific and technical merit of the research proposed sufficient to advance the objectives of the RFA? o Innovation: Does the project employ novel concepts, approaches or method? Are the aims original and innovative? Does the project challenge existing paradigms or develop new methodologies or technologies? o Investigator: Are the Principal Investigator and staff appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? o Integration with other resources: Are the plans adequate to integrate the resulting genome resources with those of other investigators and make them available to the community in a timely manner? o Environment: Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? o Budget and duration: Are the proposed budget and duration appropriate in relation to the proposed research? Availability of special opportunities for furthering research programs through the use of unusual talent resources, populations, or environmental conditions in other countries which are not readily available in the United States or which provide augmentation of existing U.S. resources will be considered in the review. The initial review group also will examine the provisions for the protection of human and animal subjects, and the safety of the research environment. AWARD CRITERIA The anticipated date of award is September 30, 1998. Factors that will be used to make award decisions are as follows: o Quality of the proposed project as determined by peer review; o Cost effectiveness of the proposed strategy; o Promise of the proposed program to accomplish the goals of this RFA and address the needs of the participating ICs/Centers as regards their interest in the zebrafish as a model organism; o Quality of the plans to cooperate and share data and resources with other projects that may be funded under this RFA in a timely manner; o Availability of funds. INQUIRIES Written and telephone inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Dr. David G. Badman Division of Kidney, Urologic and Hematologic Diseases National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive, Room 6AS-13C MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-7717 FAX: (301) 480-3510 Email: David_Badman@nih.gov Dr. Adam Felsenfeld National Human Genome Research Institute 38 Library Drive, Room 614, MSC 6050 Bethesda, MD 20892-6050 Telephone: (301) 496-7531 FAX: (301) 480-2770 Email: felsenfa@odder.nhgri.nih.gov Programmatic contacts for the other participating ICs are: Dr. Deborah Henken Center for Research for Mothers and Children National Institute for Child Health and Human Development 6100 Executive Boulevard, Room 4B01 MSC-7510 Bethesda, MD 20892-7510 Telephone: (301) 496-5541 FAX: (301) 402-4083 Email: HenkenD@hd01.nichd.nih.gov Dr. Grace L. Shen Division of Cancer Biology National Cancer Institute 6130 Executive Boulevard, Room 501 Rockville, MD 20892-7381 Telephone: (301) 435-5226 FAX: (301) 496-8656 Email: gs35r@nih.gov Dr. Judith H. Greenberg Division of Genetics and Developmental Biology National Institute of General Medical Sciences 45 Center Drive, MSC 6200 Bethesda, MD 20892-6200 Telephone: (301) 594-0943 FAX: (301) 480-2228 Email: greenbej@nigms.nih.gov Dr. Carol H. Letendre Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute 6701 Rockledge Drive, MSC 7950 Bethesda, MD 20892-7950 Telephone: (301) 435-0080 FAX: (301) 480-0867 Email: letendrc@gwgate.nhlbi.nih.gov Dr. Maria Y. Giovanni Fundamental Retinal Processes National Eye Institute Executive Plaza South, Suite 350 - MSC 7164 Bethesda, MD 20892-7164 Telephone: (301) 496-0484 FAX: (301) 402-0528 Email: myg@nei.nih.gov Dr. Robert W. Karp Division of Basic Research National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 402, MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-4223 FAX: (301) 594-0673 Email: rkarp@willco.niaaa.nih.gov Dr. Judy A. Small Division of Fundamental Neurosciences and Developmental Disorders National Institute of Neurological Disorders and Stroke 7550 Wisconsin Avenue, Room 8C04 Bethesda, MD 20892-9170 Telephone: (301) 496-5821 FAX: (301) 402-0887 Email: js134h@nih.gov Dr. Chyren Hunter Division of Human Communication National Institute on Deafness and Other Communication Disorders 6120 Executive Boulevard, Room 400-C, MSC-7180 Bethesda MD 20982-7180 Telephone: (301) 402-3461 FAX: (301) 402-6251 Email: Chyren_Hunter@nih.gov Dr. Theresa Lee Division of Basic Research National Institute on Drug Abuse 5600 Fishers Lane, Room 10A19 Rockville, MD 20857 Telephone: (301) 443-6300 FAX: (301) 594-6043 Email: tl37h@nih.gov Dr. Steven O. Moldin Division of Basic and Clinical Neuroscience Research National Institute of Mental Health 5600 Fishers Lane, Room 10C-26 Rockville, MD 20857 Telephone: (301) 443-2037 FAX: (301) 443-9890 Email: smoldin@nih.gov Dr. Elaine Young Comparative Medicine National Center for Research Resources 6705 Rockledge Drive, Room 6164 MSC 7965 Bethesda, MD 20892-7965 Telephone: (301) 435-0776 FAX: (301) 480-3659 Email: elainey@ep.ncrr.nih.gov Direct inquiries regarding fiscal and administrative matters to: Aretina Perry-Jones Division of Extramural Activities National Institute of Diabetes and Digestive and Kidney Diseases 45 Center Drive, Room 6AN-38B, MSC 6600 Bethesda, MD 20892-6600 Telephone: (301) 594-8862 FAX: (301) 480-3504 Email: PerryA@extra.niddk.nih.gov Fiscal and administrative contacts for the other participating ICs are: Mr. E. Douglas Shawver Grants Management Branch National Institute for Child Health and Human Development 6100 Executive Boulevard, Room 8A17, MSC-7510 Bethesda, MD 20892-7510 Telephone: (301) 496-1303 FAX: (301) 402-0915 Email: Shawver@hd01.nichd.nih.gov Mr. Bill Wells Grants Administration Branch National Cancer Institute 6120 Executive Boulevard, Room 243 Bethesda, MD 20892 Rockville, MD 20852 (express/courier service) Telephone: (301) 496-7800, ext. 250 FAX: (301) 496-8601 Email: WW14J@NIH.gov Ms. Marcia Cohn Grants Management Office National Institute of General Medical Sciences 45 Center Drive, Room 2AN-44E, MSC 6200 Bethesda, MD 20892-6200 Telephone: (301) 594-3918 FAX: (301) 480-1969 Email: cohnm@nigms.nih.gov Ms. Jean Cahill Grants Management Office National Human Genome Research Institute 38 Library Drive, Room 613, MSC 6050 Bethesda, MD 20892-6050 Telephone: (301) 402-0733 FAX: (301) 402-1951 Email: cahillj@odder.nhgri.nih.gov Ms. Jane R. Davis Division of Extramural Affairs National Heart, Lung, and Blood Institute 6701 Rockledge Drive, MSC 7926 Bethesda, MD 20892-7926 Telephone: (301) 435-0166 FAX: (301) 480-3310 Email: jane_davis@nih.gov Ms. Carolyn E. Grimes Grants Management Branch National Eye Institute Executive Plaza South, Suite 350, MSC 7164 Bethesda, MD 20892-7164 Telephone: (301) 496-5884 FAX: (301) 496-9997 Email: cegrimes@nei.nih.gov Ms. Linda Hilley Office of Planning and Resource Management National Institute on Alcohol Abuse and Alcoholism 6000 Executive Boulevard, Suite 504, MSC 7003 Bethesda, MD 20892-7003 Telephone: (301) 443-4703 FAX: (301) 443-3891 Email: lhilley@willco.niaaa.nih.gov Ms. Tina Carlisle Grants Management Branch National Institute of Neurological Disorders and Stroke Federal Building, Room 1004 Bethesda, MD 20892-9190 Telephone: (301) 496-9231 FAX: (301) 402-0218 Email: tc48k@nih.gov Ms. Sharon Hunt Grants Management Office National Institute on Deafness and Other Communication Disorders 6120 Executive Boulevard, Room 400-B, MSC-7180 Bethesda, MD 20982-7180 Telephone: (301) 402-0909 FAX: (301) 402-1758 Email: SH79F@nih.gov Ms. Catherine Mills Grants Management Branch National Institute on Drug Abuse 5600 Fishers Lane, Room 8A-54 Rockville, MD 20857 Telephone: (301) 443-6710 FAX: (301) 594-6847 Email: cm108w@nih.gov Ms. Diana S. Trunnell Grants Management Branch National Institute of Mental Health 5600 Fishers Lane, Room 7C-08 Rockville, MD 20857 Telephone: (301) 443-2805 FAX: (301) 443-6885 Email: dt21a@nih.gov Ms. Louise Amburgey Office of Grants Management National Center for Research Resources 6705 Rockledge Drive, Room 6086 MSC 7965 Bethesda, MD 20892-7965 Telephone: (301) 435-0844 FAX: (301) 480-3777 Email: louisem@ep.ncrr.nih.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.849 (Kidney, Urologic and Hematologic Research). Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |